TOP TEN perturbations for 38619_at (Homo sapiens)
Organism: Homo sapiens
Gene: 38619_at
Selected probe(set): 229255_x_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array
Expression of 38619_at (229255_x_at) across 6674 perturbations tested by GENEVESTIGATOR:
atopic dermatitis study 21 (lesional; whole skin) / normal skin tissue
Relative Expression (log2-ratio):1.9286308Number of Samples:5 / 6
| Experimental | atopic dermatitis study 21 (lesional; whole skin) |
| Lesional full thickness skin samples isolated from patient with moderate-to-severe atopic dermatitis by laser capture microdissection. Patients' cohort characteristics: 3 males and 2 females; age 27-59 years (mean age: 39.4 years); SCORing of Atopic Dermatitis index (SCORAD) ranging from 45-65; total IgE: 14-1821 kU/l; eosinophilic count: 1.4-11.8 %. | |
| Control | normal skin tissue |
| Full thickness skin samples isolated from healthy subjects by laser capture microdissection. |
stem cell differentiation study 50 (IRF2 shRNA; ASC; proerythroblast) / stem cell differentiation study 50 (mock shRNA; ASC; proerythroblast)
Relative Expression (log2-ratio):1.823247Number of Samples:3 / 4
| Experimental | stem cell differentiation study 50 (IRF2 shRNA; ASC; proerythroblast) |
| Proerythroblast differentiated from IRF2 (interferon regulatory factor 2) shRNA transduced hematopoietic stem/progenitor cells (CD34+). CD34+ hematopoietic stem/progenitor cells (HSC) were transduced with lentivirus expressing shRNA targeting IRF2 gene with following differentiation to the erythroid lineage. HSCs were obtained from magnetically sorted G-CSF mobilized peripheral blood mononuclear cells of healthy donors. Cells were expanded in StemSpan SFEM medium supplied with Flt-3 ligand (100 ng/ml), SCF (100 ng/ml), IL-3 (20 ng/ml), IL-6 (20 ng/ml) and penicillin/streptomycin. Cells were harvested for total RNA extraction at the proerythroblast stage of differentiation. | |
| Control | stem cell differentiation study 50 (mock shRNA; ASC; proerythroblast) |
| Proerythroblast differentiated from control shRNA transduced hematopoietic stem/progenitor cells (CD34+). CD34+ hematopoietic stem/progenitor cells (HSC) were transduced with lentivirus expressing control shRNA with following differentiation to the erythroid lineage. HSCs were obtained from magnetically sorted G-CSF mobilized peripheral blood mononuclear cells of healthy donors. Cells were expanded in StemSpan SFEM medium supplied with Flt-3 ligand (100 ng/ml), SCF (100 ng/ml), IL-3 (20 ng/ml), IL-6 (20 ng/ml) and penicillin/streptomycin. Cells were harvested for total RNA extraction at the proerythroblast stage of differentiation. |
stem cell differentiation study 50 (IRF6 shRNA; ASC; proerythroblast) / stem cell differentiation study 50 (mock shRNA; ASC; proerythroblast)
Relative Expression (log2-ratio):1.7615614Number of Samples:3 / 4
| Experimental | stem cell differentiation study 50 (IRF6 shRNA; ASC; proerythroblast) |
| Proerythroblast differentiated from IRF6 (interferon regulatory factor 6) shRNA transduced hematopoietic stem/progenitor cells (CD34+). CD34+ hematopoietic stem/progenitor cells (HSC) were transduced with lentivirus expressing shRNA targeting IRF6 gene with following differentiation to the erythroid lineage. HSCs were obtained from magnetically sorted G-CSF mobilized peripheral blood mononuclear cells of healthy donors. Cells were expanded in StemSpan SFEM medium supplied with Flt-3 ligand (100 ng/ml), SCF (100 ng/ml), IL-3 (20 ng/ml), IL-6 (20 ng/ml) and penicillin/streptomycin. Cells were harvested for total RNA extraction at the proerythroblast stage of differentiation. | |
| Control | stem cell differentiation study 50 (mock shRNA; ASC; proerythroblast) |
| Proerythroblast differentiated from control shRNA transduced hematopoietic stem/progenitor cells (CD34+). CD34+ hematopoietic stem/progenitor cells (HSC) were transduced with lentivirus expressing control shRNA with following differentiation to the erythroid lineage. HSCs were obtained from magnetically sorted G-CSF mobilized peripheral blood mononuclear cells of healthy donors. Cells were expanded in StemSpan SFEM medium supplied with Flt-3 ligand (100 ng/ml), SCF (100 ng/ml), IL-3 (20 ng/ml), IL-6 (20 ng/ml) and penicillin/streptomycin. Cells were harvested for total RNA extraction at the proerythroblast stage of differentiation. |
atopic dermatitis study 21 (non-lesional; whole skin) / normal skin tissue
Relative Expression (log2-ratio):1.7411089Number of Samples:5 / 6
| Experimental | atopic dermatitis study 21 (non-lesional; whole skin) |
| Non-lesional full thickness skin samples isolated from patient with moderate-to-severe atopic dermatitis by laser capture microdissection. Patients' cohort characteristics: 3 males and 2 females; age 27-59 years (mean age: 39.4 years); SCORing of Atopic Dermatitis index (SCORAD) ranging from 45-65; total IgE: 14-1821 kU/l; eosinophilic count: 1.4-11.8 %. | |
| Control | normal skin tissue |
| Full thickness skin samples isolated from healthy subjects by laser capture microdissection. |
IgA nephropathy study 8 / control glomerulus tissue
Relative Expression (log2-ratio):1.6456776Number of Samples:20 / 20
| Experimental | IgA nephropathy study 8 |
| Hand-microdissected glomerular tissue samples derived from kidney biopsies of patients with IgA nephropathy (IgAN). Whole-core patient biopsies were obtained as part of routine renal biopsy procedures. | |
| Control | control glomerulus tissue |
| Hand-microdissected glomerular tissue samples derived from kidney biopsies of healthy living kidney transplant donors. The biopsies were taken after reperfusion in the kidney transplant recipient. |
brefeldin A study 1 (0.5ug/ml; HCT 116 DICER1(-/-)) / tunicamycin study 2 (2ug/ml; HCT 116 DICER1(-/-))
Relative Expression (log2-ratio):1.6038437Number of Samples:3 / 3
| Experimental | brefeldin A study 1 (0.5ug/ml; HCT 116 DICER1(-/-)) |
| Derived human colon carcinoma cell line HCT 116 DICER1(-/-) with knockout DICER gene in exon 5 was treated with 0.5 ug/ml brefeldin-A for 24 hours in McCOYs 5A medium supplemented with 10% heat inactivated FBS. ATC code:--- | |
| Control | tunicamycin study 2 (2ug/ml; HCT 116 DICER1(-/-)) |
| Derived human colon carcinoma cell line HCT 116 DICER1(-/-) with knockout DICER gene in exon 5 was treated with 2 ug/ml tunicamycin for 24 hours in McCOYs 5A medium supplemented with 10% heat inactivated FBS. ATC code:--- |
benzo[a]pyrene study 2 (2 uM; Hep-G2) / vehicle (DMSO) treated Hep-G2 cell sample
Relative Expression (log2-ratio):1.6028833Number of Samples:3 / 9
| Experimental | benzo[a]pyrene study 2 (2 uM; Hep-G2) |
| Hep-G2 cells exposed to 2 uM benzo[a]pyrene (dissolved in 0.5% v/v DMSO) for 72 hours. Cells were exposed to the chemical when 80% confluence was reached. Cells were treated with the IC10 determined by a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide test (number of replicates, n = 3). ATC code:--- | |
| Control | vehicle (DMSO) treated Hep-G2 cell sample |
| Hep-G2 cells treated with vehicle (DMSO 0.5% v/v) for 72 hours. Cells were exposed to the vehicle when 80% confluence was reached. |
conditioned medium study 1 (HS5) / untreated monocyte (CD14+) sample
Relative Expression (log2-ratio):1.5855656Number of Samples:2 / 2
| Experimental | conditioned medium study 1 (HS5) |
| CD14+ monocytes treated with HS5 conditioned medium (CM) for 48h. | |
| Control | untreated monocyte (CD14+) sample |
| Untreated CD14+ monocytes from two different donors. |
adrenal gland cancer study 4 / normal adrenal cortex tissue
Relative Expression (log2-ratio):1.4948854Number of Samples:43 / 4
| Experimental | adrenal gland cancer study 4 |
| Primary tumor tissue samples of the adrenal cortex from patients with adrenocortical carcinoma (ACC). | |
| Control | normal adrenal cortex tissue |
| Histological normal adrenal gland cortical tissue samples derived after autopsy. |
conditioned medium study 1 (HS27a) / untreated monocyte (CD14+) sample
Relative Expression (log2-ratio):1.3751316Number of Samples:2 / 2
| Experimental | conditioned medium study 1 (HS27a) |
| CD14+ monocytes treated with HS27a conditioned medium (CM) for 48h. | |
| Control | untreated monocyte (CD14+) sample |
| Untreated CD14+ monocytes from two different donors. |